CAG方案治疗老年人急性髓细胞白血病20例疗效观察
被引量:5
摘要
老年急性髓细胞白血病患者有其临床特点:细胞恶性程度高,常规化疗不易缓解。且患者存在多脏器功能减退,限制了化疗药物的选用和使用剂量,化疗风险大,早期化疗相关死亡率高,生存期短。
出处
《贵州医药》
CAS
2011年第11期991-992,共2页
Guizhou Medical Journal
参考文献3
-
1朱薇波,潘理明.老年人急性白血病27例分析[J].中国临床保健杂志,2000,6(1):10-11. 被引量:1
-
2孙爱宁,苗瞄,仇惠英,夏学鸣,陶瑞芳.老年急性髓细胞性白血病的生物学及临床特征研究[J].临床荟萃,2000,15(18):825-826. 被引量:1
-
3苏贵平,汪兴洪,黄东平,戴艳,姚军萍.预激方案治疗老年和难治性急性髓系白血病疗效观察[J].白血病.淋巴瘤,2007,16(1):57-58. 被引量:5
二级参考文献9
-
1刘征辉,张学光,夏学鸣,郑列琳,陆廷伟,薛永权,阮长耿.免疫表型在急性髓细胞白血病中的预后价值[J].中华血液学杂志,1996,17(11):588-591. 被引量:22
-
2Bishop J F. Adult acute myeloid leukemia: update on treatment[J]. Aust, 1999, 4(170): 39-43.
-
3Saito k, Nakamura Y, Aoyagi M, et al. Low-dose cytarabine and aclarubicin in combination with granulocyte relapsed or primary resistant acute myelogenous leukemia (AML) and previoualy untreated eider patients with AML, secondary AML, and refractory anemia with excess blasts in transformation[J]. Int J Hcmatol, 2000, 71(3):283-244.
-
4Bai A, Kojima H, Hori M, et al. Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells[J]. Exp Hematol, 1999, 27(2): 259-265.
-
5Yamada K, Furusawa S, Sito K, et al. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubingcin for previously treated acute myelogenous leukemia: a pilot study[J]. Leukemia, 1995, 9(1): 10-14.
-
6Lowenberg B, Suciu S, Archimband E, et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11.a phase Ⅲ randomized study of the leukemia Cooperative Group of European Organization for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group[J]. Blood, 1997, 90(8): 2952-2961.
-
7Stone R M. The difficult problem of acute myeloid leukemia in the older aduh[J]. CA Cancer J Clin, 2002, 52(6): 363-367.
-
8Tilly H,et al.Low-dose cytosine arabinoside treatmen for acute monlymphocytic leukaemia in elderly patients[].Cancer.1989
-
9Tilly H,et al.Low-dose cytarabine versus intensive chemotherapy in the elderly[].Journal of Clinical Oncology.1990
共引文献4
-
1刘加强,冷静,桑磊,李同英.小剂量CHG预激方案治疗老年人急性髓系白血病的临床研究[J].白血病.淋巴瘤,2010,19(6):347-348. 被引量:3
-
2梁虹,赵海军.CAG预激方案治疗急性髓系白血病及骨髓增生异常综合征[J].白血病.淋巴瘤,2010,19(10):607-609. 被引量:14
-
3许锦霞,魏旭东,尹青松,米瑞华,宋永平.CAG方案联合三氧化二砷、维甲酸治疗伴C-kit及FLT3表达的骨髓增生异常综合征一例并文献复习[J].白血病.淋巴瘤,2013,22(4):246-247.
-
4林芝,赵少勇,黄世华,龚光,陈昌茜,陈丹.预激方案治疗老年高危骨髓增生异常综合征的临床研究[J].中国医药导刊,2015,17(6):580-582. 被引量:1
同被引文献49
-
1孙少勤,周小代,谢阳阳.地西他滨联合CAG方案治疗老年及复发难治急性髓系白血病的效果研究[J].世界临床医学,2017,11(8):111-111. 被引量:6
-
2李映雪,何志旭.79例急性白血病患者死亡原因调查分析[J].贵州医药,2011,35(4):361-362. 被引量:1
-
3陈红燕,王宝佳,谢东,郑启珠,陈德友,田萍.急性白血病的化疗相关感染分析[J].中国药业,2005,14(1):67-68. 被引量:4
-
4Riccardo M, Katharina K, Carlotta B, et al. Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia[J]. Recent Patents on Anti - Can-cer Drug Discovery,2011,6(3) :354 - 366.
-
5Sigal T, Einam R, Nadav S. High Response Rate for Treatment With Gem-tuzumab Ozogamicin and Cytarabine in Elderly Patients With Acute Myeloid Leukemia and Favorable and Intermediate - I Cytogenetic Risk[J]. Clinical Lymphoma Myeloma and Leukemia,2012,12(6) :438 - 443.
-
6Tarraga Lopez PJ, Albert) JS, Rodriquez-Montes JA. Primary and sec-ondary prevention of colorectal cancer[ J]. Clin Med Insights Gastroen-terol,2014,7 :33-46.
-
7Timme CR,Gruidl M,Yeatman TJ. Gamma-secretase inhibition attenu-ates oxaliplatin-induced apoptosis through increased Mcl-1 and/or Bcl-xL in human colon cancer cells[ J]. Apoptosis,2013 ,18(10) : 1163-1174.
-
8Sun JG,Xiang J,Zeng XL, et al. Clitocine induces apoptosis and en-hances the lethality of ABT-737 in human colon cancer cells by disrup-ting the interaction of Mcl-1 and Bak[ J] . Cancer Lett,2014,355(2):253-263.
-
9Mhaidat NM,Alzoubi KH,Al-Azzam SI,et al. Caffeine inhibits paclita-xel induced apoptosis in colorectal cancer cells through the upregula-tion of Mcl 1 levels [J]. Mol Med Rep,2014,9( 1) :243-248.
-
10Ertel F, Nguyen M, Roulston A, et al. Programming cancer cells forhigh expression levels of Mcll [ J]. EMBO Rep,2013,14(4) :328-336.
引证文献5
-
1苏杰.CAG与HAG方案治疗老年急性髓系白血病疗效对比[J].中国药业,2014,23(15):114-116. 被引量:3
-
2施莉,韦炜,向华,薛向阳,叶璐璐,范波.人MCL1不同亚型在结肠癌中表达变化的临床意义[J].中华全科医学,2015,13(10):1576-1578.
-
3王继芳,魏秀丽,郭莉,任荣香,田丽丽,苏婷婷,吴志敏.地西他滨联合CAG方案治疗难治复发急性髓系白血病的疗效观察[J].中国医药指南,2016,14(27):16-17. 被引量:9
-
4汪梅花,赵康,葛繁梅.去甲基化药物联合CAG方案治疗老年白血病或难治复发性白血病疗效观察及对VEGF、bFGF的影响研究[J].临床和实验医学杂志,2018,17(3):311-314. 被引量:16
-
5顾丽丽,何涛.地西他滨联合CAG方案治疗老年急性髓系白血病的疗效观察[J].中国医院用药评价与分析,2018,18(5):613-615. 被引量:14
二级引证文献41
-
1陈建玲.地西他滨联合CAG方案治疗老年性及复发难治性急性髓细胞白血病疗效及副作用观察[J].黑龙江中医药,2021,50(5):1-2. 被引量:1
-
2孙少勤,周小代,谢阳阳.地西他滨联合CAG方案治疗老年及复发难治急性髓系白血病的效果研究[J].世界临床医学,2017,11(8):111-111. 被引量:6
-
3张志明,佟丽.中医养阴清热透邪法联合DA化疗方案治疗老年急性髓系白血病的临床观察[J].中国中医急症,2016,25(6):1248-1250. 被引量:5
-
4陈杰甫,武永强,杨淑杰,唐广.地西他滨联合CAG方案治疗老年急性髓系白血病临床效果[J].淮海医药,2017,35(3):276-277. 被引量:8
-
5高志宏,赵爱红,陈方.减低剂量的地西他滨联合CAG方案治疗中高危骨髓增生异常综合征及难治性白血病的疗效分析[J].系统医学,2017,2(8):1-5. 被引量:3
-
6陈小敏.地西他滨联合CAG方案治疗老年急性髓系白血病的效果和安全性分析[J].中外医学研究,2018,16(1):8-9. 被引量:2
-
7耿素红,王微娜.地西他滨联合改良CAG方案治疗复发、难治性急性髓系白血病的疗效观察[J].中国医院用药评价与分析,2018,18(4):509-510. 被引量:10
-
8徐长荣,金阿荣.地西他滨治疗急性髓系白血病疗效观察[J].中国实用医药,2018,13(15):134-135.
-
9何程明.地西他滨治疗老年急性髓系白血病的疗效分析[J].基层医学论坛,2018,22(32):4555-4556.
-
10沈绿瑛.不同剂量地西他滨序贯低剂量化疗方案治疗急性髓系白血病的临床效果观察[J].临床合理用药杂志,2018,11(29):71-72. 被引量:1
-
1陶丽菊,杨丽艳.老年人急性髓细胞白血病个体化治疗疗效观察[J].临床荟萃,2000,15(18):828-829. 被引量:1
-
2林凤茹.提高老年人急性髓细胞白血病疗效策略的探讨[J].白血病,2000,9(6):370-371. 被引量:4
-
3李建勇,华东,夏学鸣,王玮,陈子兴,阮长耿.老年人急性髓细胞白血病P-糖蛋白表达的临床意义[J].中华老年医学杂志,1998,17(4):201-203.
-
4陈芾珩,苏永忠,刘元生,庄春兰,李回军.小剂量三尖杉酯碱和阿糖胞苷联合粒细胞集落刺激因子治疗老年急性髓细胞白血病疗效观察[J].中国基层医药,2009,16(2):247-248. 被引量:3
-
5魏建平,杨晓云,顾惜春,朱玲.老年人急性髓细胞白血病不同剂量化疗疗效观察[J].临床血液学杂志,1999,12(5):233-234. 被引量:2
-
6孙妍珺,陈佳,徐杨,吴德沛.老年人急性髓细胞白血病的治疗进展[J].国际输血及血液学杂志,2016,39(1):60-64. 被引量:4
-
7宋德余,高增书,李朋英,张书亭,薛亚静,王国立,杨进强,朱玉庆.腹腔肿瘤术后旱期化疗对机体免疫功能的影响[J].世界华人消化杂志,1999,7(5):450-451. 被引量:1
-
8王东华,陈晨明,韩淑花.进展期胃癌术后早期化疗的体会[J].黑龙江医学,1999(4):23-24.
-
9姚兴伟,杜志刚,李娟,许亚民.21例大肠癌早期化疗疗效观察[J].山东医药,2007,47(17):18-18.
-
10王吉水.术后早期化疗在直肠癌患者治疗中的作用探讨[J].中国继续医学教育,2017,9(4):119-120. 被引量:2